Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.0K
Directing Effect of Substituents: meta-Directing Groups01:09

Directing Effect of Substituents: meta-Directing Groups

6.0K
Substituents on the benzene ring that direct an incoming electrophile to undergo substitution at the meta position are called meta directors. All meta directors either have a positive charge on the atom directly bonded to the ring or a partial positive charge. These groups function by withdrawing electrons from the ring through inductive and resonance effects. Consider the carbocation intermediates formed upon the addition of an electrophile on nitrobenzene at the...
6.0K
Directing Effect of Substituents: ortho–para-Directing Groups01:14

Directing Effect of Substituents: ortho–para-Directing Groups

8.5K
Ortho–para directors are substituent groups attached to the benzene ring and direct the addition of an electrophile to the positions ortho or para to the substituent. All electron-donating groups are considered ortho–para directors. They donate electrons to the ring and make the ring more electron-rich. The ring is therefore susceptible to the addition of electrophiles. Substituents such as amino, hydroxy, or alkoxy, containing lone pairs on the atom adjacent to the ring, donate...
8.5K
Directional Terms01:14

Directional Terms

16.4K
Directional terms are essential for describing the relative locations of different body structures. For instance, an anatomist might describe one band of tissue as "inferior to" another, or a physician might describe a tumor as "superficial to" a deeper body structure. These terms often use comparative terms in pairs to trace out the relative locations of one body part to another or descriptions of body tissues like the deeper ones from superficially present with reference to...
16.4K
Directional Relays01:25

Directional Relays

614
Directional relays, essential for managing unidirectional fault currents, enhance the safety and efficiency of power systems. On power lines equipped with directional relays, faults downstream (to the right) of the current transformer typically cause the fault current to lag the bus voltage by approximately 90 degrees, known as the forward direction. In contrast, upstream (left-side) faults may result in the fault current leading the bus voltage by nearly 90 degrees, termed the reverse...
614
Direct Motor Pathways01:11

Direct Motor Pathways

4.5K
The direct motor pathways, also known as the pyramidal tracts, are a group of neural pathways that originate in the brain and descend through the spinal cord. They control the voluntary movement of the body. There are two major direct motor pathways: the corticospinal and the corticobulbar tracts.
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

ESMO gastrointestinal oncology·2026
Same author

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

ESMO open·2026
Same author

Fertility and sexuality in early-onset colorectal cancer patients: a monocentric survey.

ESMO gastrointestinal oncology·2026
Same author

Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study).

Clinical colorectal cancer·2024
Same author

Determination of nine new fentanyl analogues and metabolites in consumers' urine by ultra-high-performance liquid chromatography-tandem mass spectrometry.

European review for medical and pharmacological sciences·2021
Same author

Outcomes of cementless fixation in medial unicompartmental knee arthroplasty: review of recent literature.

Musculoskeletal surgery·2020

Related Experiment Video

Updated: Feb 3, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

CPX-351: From preclinical studies to future directions.

A Sperotto1, G Ciotti2, M Basso3

  • 1UOSD Terapie Cellulari - Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV) - IRCCS - Padova, Italy; UOC Oncoematolgia - Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV) - IRCCS - Padova, Italy.

Current Opinion in Pharmacology
|February 1, 2026
PubMed
Summary

CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, is approved for secondary acute myeloid leukemia (AML). This review covers its development, toxicity, and therapeutic applications.

More Related Videos

An Experimental Approach to Investigating Effects of Artificial Light at Night on Free-Ranging Animals: Implementation, Results, and Directions for Future Research
06:16

An Experimental Approach to Investigating Effects of Artificial Light at Night on Free-Ranging Animals: Implementation, Results, and Directions for Future Research

Published on: February 2, 2022

2.9K
3D Kinematic Gait Analysis for Preclinical Studies in Rodents
10:19

3D Kinematic Gait Analysis for Preclinical Studies in Rodents

Published on: August 3, 2019

11.3K

Related Experiment Videos

Last Updated: Feb 3, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
An Experimental Approach to Investigating Effects of Artificial Light at Night on Free-Ranging Animals: Implementation, Results, and Directions for Future Research
06:16

An Experimental Approach to Investigating Effects of Artificial Light at Night on Free-Ranging Animals: Implementation, Results, and Directions for Future Research

Published on: February 2, 2022

2.9K
3D Kinematic Gait Analysis for Preclinical Studies in Rodents
10:19

3D Kinematic Gait Analysis for Preclinical Studies in Rodents

Published on: August 3, 2019

11.3K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The standard induction treatment for acute myeloid leukemia (AML) has been the 7+3 regimen.
  • Secondary AML presents unique treatment challenges.
  • CPX-351 (Vyxeos) offers a novel liposomal formulation of cytarabine and daunorubicin.

Purpose of the Study:

  • To review the development of CPX-351 from preclinical research to FDA approval.
  • To analyze the efficacy and safety profile of CPX-351.
  • To discuss current and potential future applications of CPX-351 in AML treatment.

Main Methods:

  • Review of preclinical studies.
  • Analysis of clinical trial data.
  • Examination of regulatory submission and approval process.

Main Results:

  • CPX-351, utilizing CombiPlex technology, demonstrated a synergistic 5:1 ratio of cytarabine and daunorubicin.
  • FDA approval in August 2017 for adults with newly diagnosed secondary AML.
  • Recent research indicates potential intestinal and heart toxicity.

Conclusions:

  • CPX-351 represents a significant advancement in AML therapy.
  • Understanding its toxicity profile is crucial for patient management.
  • Further research may expand its therapeutic utility in AML and other malignancies.